Lantz Financial LLC Decreases Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Lantz Financial LLC lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 0.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 25,600 shares of the biopharmaceutical company’s stock after selling 214 shares during the period. Lantz Financial LLC’s holdings in Gilead Sciences were worth $2,365,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Public Sector Pension Investment Board increased its holdings in Gilead Sciences by 72.9% during the 2nd quarter. Public Sector Pension Investment Board now owns 47,722 shares of the biopharmaceutical company’s stock worth $3,274,000 after purchasing an additional 20,120 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of Gilead Sciences during the second quarter worth approximately $8,269,000. Point72 Asset Management L.P. increased its stake in shares of Gilead Sciences by 43.2% in the second quarter. Point72 Asset Management L.P. now owns 512,125 shares of the biopharmaceutical company’s stock worth $35,137,000 after buying an additional 154,525 shares during the last quarter. Fred Alger Management LLC raised its holdings in Gilead Sciences by 9.8% in the second quarter. Fred Alger Management LLC now owns 27,357 shares of the biopharmaceutical company’s stock valued at $1,877,000 after acquiring an additional 2,442 shares in the last quarter. Finally, Dark Forest Capital Management LP boosted its stake in Gilead Sciences by 119.2% during the 2nd quarter. Dark Forest Capital Management LP now owns 6,072 shares of the biopharmaceutical company’s stock valued at $417,000 after acquiring an additional 3,302 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have recently commented on GILD shares. UBS Group increased their price target on shares of Gilead Sciences from $70.00 to $96.00 and gave the stock a “neutral” rating in a research report on Thursday, November 21st. Piper Sandler increased their target price on Gilead Sciences from $95.00 to $105.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Wells Fargo & Company boosted their price target on Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Wolfe Research began coverage on Gilead Sciences in a research note on Friday, November 15th. They set an “outperform” rating and a $110.00 price objective on the stock. Finally, Oppenheimer lifted their price objective on shares of Gilead Sciences from $105.00 to $115.00 and gave the stock an “outperform” rating in a report on Tuesday, December 10th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have given a strong buy rating to the company. According to MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus target price of $97.96.

Gilead Sciences Trading Up 0.2 %

Shares of GILD stock opened at $93.07 on Friday. The firm has a market capitalization of $115.99 billion, a PE ratio of 1,034.11, a price-to-earnings-growth ratio of 1.31 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $98.90. The stock has a fifty day moving average of $91.74 and a two-hundred day moving average of $84.86.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping the consensus estimate of $1.58 by $0.44. The business had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The company’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.29 earnings per share. As a group, research analysts expect that Gilead Sciences, Inc. will post 4.36 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were paid a dividend of $0.77 per share. The ex-dividend date of this dividend was Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.31%. Gilead Sciences’s dividend payout ratio is presently 3,422.22%.

Insider Buying and Selling

In other news, insider Merdad Parsey sold 25,590 shares of Gilead Sciences stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the transaction, the insider now directly owns 99,599 shares in the company, valued at approximately $9,113,308.50. This trade represents a 20.44 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the sale, the chief financial officer now owns 129,873 shares of the company’s stock, valued at approximately $11,863,898.55. This trade represents a 1.89 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 456,234 shares of company stock valued at $42,130,461 over the last quarter. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.